ETON übertreffen die 12 der letzten 26Schätzungen.
46%
Nächster Bericht
Datum des nächsten Berichts
16. März 2026
Estimate forQ4 25(Revenue/ EPS)
$20.99M
/
$0.09
Implizierte Änderung vonQ3 25(Revenue/ EPS)
-6.54%
/
-228.57%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+80.22%
/
-550.00%
Eton Pharmaceutcials, Inc. Common Stock earnings per share and revenue
On 06. Nov. 2025, ETON reported earnings of -0.07 USD per share (EPS) for Q3 25, missing the estimate of 0.09 USD, resulting in a -176.25% surprise. Revenue reached 22.46 million, compared to an expected 20.88 million, with a 7.54% difference. The market reacted with a -11.70% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of 0.09 USD, with revenue projected to reach 20.99 million USD, implying an decrease of -228.57% EPS, and decrease of -6.54% in Revenue from the last quarter.
FAQ
What were Eton Pharmaceutcials, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Eton Pharmaceutcials, Inc. Common Stock reported EPS of -$0.07, missing estimates by -176.25%, and revenue of $22.46M, 7.54% above expectations.
How did the market react to Eton Pharmaceutcials, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -11.7%, changed from $19.14 before the earnings release to $16.90 the day after.
When is Eton Pharmaceutcials, Inc. Common Stock expected to report next?
The next earning report is scheduled for 16. März 2026.
What are the forecasts for Eton Pharmaceutcials, Inc. Common Stock's next earnings report?
Based on 5
analysts, Eton Pharmaceutcials, Inc. Common Stock is expected to report EPS of $0.09 and revenue of $20.99M for Q4 2025.